Skip to main content
PLOS Digital Health logoLink to PLOS Digital Health
. 2023 Feb 27;2(2):e0000201. doi: 10.1371/journal.pdig.0000201

A systematic review to explore how exercise-based physiotherapy via telemedicine can promote health related benefits for people with cystic fibrosis

Ben Bowhay 1, Jos M Latour 2, Owen W Tomlinson 3,*
Editor: Yuan Lai4
PMCID: PMC9970050  PMID: 36848358

Abstract

To conduct a systematic review to evaluate the effects of physiotherapy exercises delivered via telemedicine on lung function and quality-of-life in people with Cystic Fibrosis (CF). The databases AMED, CINAHL and MEDLINE were searched from December 2001 until December 2021. Reference lists of included studies were hand-searched. The PRISMA 2020 statement was used to report the review. Studies of any design reported in the English language, included participants with CF, and within outpatient settings were included. Meta-analysis was not deemed appropriate due to the diversity of interventions and heterogeneity of the included studies. Following screening, eight studies with 180 total participants met the inclusion criteria. Sample sizes ranged from 9 to 41 participants. Research designs included five single cohort intervention studies, two randomised control trials and one feasibility study. Telemedicine-based interventions included Tai-Chi, aerobic, and resistance exercise delivered over a study period of six to twelve weeks. All included studies which measured percentage predicted forced expiratory volume in one second found no significant difference. Five studies measuring the Cystic Fibrosis Questionnaire–Revised (CFQ-R) respiratory domain found improvements, however, did not meet statistical significance. For the CFQ-R physical domain, measured by five studies, two studies found an improvement, although not statistically significant. No adverse events were reported across all studies. The included studies indicate that telemedicine-based exercise over 6–12 weeks does not significantly change lung function or quality-of-life in people with CF. Whilst the role of telemedicine in the care of pwCF is acceptable and promising; further research with standardised outcome measures, larger sample sizes and longer follow-up are required before clinical practice recommendations can be developed.

Author summary

Preliminary evidence suggests that exercise for people with cystic fibrosis may be beneficial for lung function and quality of life improvements, but we do not know if telemedicine-based exercise can achieve similar outcomes. The current review highlighted increases within quality of life self-reported outcomes for the respiratory and physical domains, however no significant lung function improvements were found. The quality of the available evidence is low-moderate, due to poor methodological rigour and statistical power which reduces the strength of the review findings. Therefore, future large scale, high-quality randomised controlled trials with longer follow-up duration and standardised interventions would provide robust statistical evidence to optimise clinical practice and develop gold standard telemedicine-based exercise guidelines.

1. Introduction

Cystic Fibrosis (CF) is an autosomal recessive inherited disease which affects approximately 100,000 people worldwide and over 10,500 people in the United Kingdom (UK) [1,2]. Cystic fibrosis is a multisystem condition which predominantly impacts the respiratory system and is caused by a faulty gene code which regulates intra- and extra-cellular sodium chloride and water transference [3]. As a result, thickened dehydrated mucus builds up which leads to chronic airway infection, bronchiectasis and respiratory disease [4]. Consequently, respiratory failure is the primary cause of mortality in people with CF (pwCF) [5].

In the UK, life expectancy has increased to 47.3 years for pwCF following extensive research and treatment developments to maintain lung function [2]. Lung function is a key indicator of quality of life (QoL) and survival in pwCF [6]. The commonly used outcome measures to assess lung function and QoL in pwCF are percentage predicted forced expiratory volume in one second (ppFEV1) and the Cystic Fibrosis Questionnaire–Revised (CFQ-R) [7,8]. Cystic fibrosis cannot be cured, therefore maintaining lung function and improving QoL of pwCF is a key focus [7,9,10].

The National Institute of Health and Care Excellence (NICE) guidance document [NG78] recommends that specialist physiotherapists can support pwCF by designing comprehensive, individualised exercise programmes [10]. However, no specific detail about these exercise programmes are provided in the guidelines, thus placing the onus of responsibility on to individual CF teams. Physiologically, pwCF may have reduced exercise capacity when compared against the general population due to dysfunction of their ventilatory, cardiac and muscular systems which increases their risk of mortality [11].

Interventions to increase physical activity have been developed and tested, but inconsistencies in study design and outcome measures limit our understanding of how exercise can benefit pwCF [12]. As there are no specific PA guidelines for pwCF, it is recommended that all adults should take part in at least 150 minutes of moderate vigorous intensity aerobic physical activity (MVPA) or 75 minutes of vigorous intensity physical activity per week [13].

The most common outcomes of physical activities in pwCF has been explored in various studies [14]. A multicentre study found associations between physical activity and QoL in pwCF (n = 76) who performed three exercise sessions per week over a 6-month study period [15]. The relationship between ppFEV1 and CFQ-R respiratory domain from baseline to 6-month follow-up was found to have a significant correlation (p <0.01), although ppFEV1 did not have a positive correlation with the physical domain (p < 0.05), indicating that respiratory domains of QoL are closely linked to physical functioning [15]. A systematic review by Shelley et al [16]highlighted a positive relationship between ppFEV1 and physical activity based on five included studies [16]. Time spent engaging in MVPA has also been positively associated with ppFEV1 (p = 0.04) [16]. However, all these studies have been conducted face-to face, which is a burdensome approach for CF teams. Unfortunately, there is limited evidence available of CF specific telemedicine exercise programmes which serve to maintain ppFEV1 and optimise CFQ-R outcomes [17].

Telemedicine is the delivery of healthcare via technological communication methods to improve the patients’ accessibility [18]. Telemedicine is a rapidly evolving provision within the National Health Service (NHS) due to an increasing number of patients living longer with chronic conditions and the current coronavirus pandemic [19]. The World Health Organization (WHO) recently published its first global strategy for digital health [20]. Telemedicine enables pwCF to access exercise programs while conforming with infection control requirements and preventing cross-infection, a requirement that restricts group exercise participation [21]. Telemedicine research for pwCF is still in the early stages, however there has been telemedicine interventions developed to support exercise in other chronic health conditions [22].

As a first step to defining optimal telemedicine-based exercise for pwCF, it is informative to review the current evidence. Currently, there are no systematic reviews exploring telemedicine-based exercise exclusively in pwCF and therefore, the aim of this systematic review was to fill this evidence gap and evaluate telemedicine-based exercise interventions for pwCF and the impact on ppFEV1 and QoL.

2. Methods

The systematic review was conducted and reported using the PRISMA 2020 Statement [23] as a guideline.

2.1. Eligibility criteria

All full-text articles were obtained and screened for eligibility against the inclusion and exclusion criteria resented in Table 1. These eligibility criteria surrounding the population and intervention were chosen to align with the research question (i.e. only people with CF were included), and recommended physical and psychological outcome measures [10].

Table 1. Inclusion and exclusion criteria.

Selection Inclusion criteria Exclusion criteria
Population(s) Cystic fibrosis patients of all ages, genders and disease severities Non-cystic fibrosis patients
Intervention(s) Telemedicine exercise intervention to enhance QoL and/or lung function. Non-telemedicine interventions
Comparators Control where possible Not specified
Outcomes ppFEV1 and CFQ-R physical and respiratory domains Outcome does not relate to ppFEV1 or CFQ-R domains
Study design All study designs
Published in available full-text English
Over 20 years since publication
Setting Community-based intervention Face-to-face interventions

ppFEV1 = Forced Expiratory Volume in 1 second; CFQ-R = Cystic Fibrosis Questionnaire–Revised; QoL = Quality of Life

2.2. Information sources

The following databases were searched via an online research platform (EBSCOhost): AMED, CINAHL and MEDLINE; from December 2001 to December 2021. The specified date range is due to limited telemedicine interventions before this period. These databases are comprised of healthcare research which serves to support the collation of literature relevant to the purpose of this review.

2.3. Search strategy

The search was developed according to three key concepts: (1) cystic fibrosis, (2) telemedicine and (3) exercise or physical activity. Keywords were identified using MeSH terms and related synonyms:

  1. cystic fibrosis OR cf

  2. exercise OR physical activity OR fitness OR physiotherapy

  3. telemedicine OR telehealth OR telecare OR telemonitor OR telephone OR online

Boolean operators were used, with “OR” between the words in each column, and “AND” used to combine the entirety of the searches 1, 2 and 3. The reference list of included studies and review articles were also reviewed to identify any potentially relevant studies not identified through the search process.

2.4. Selection process

The database searches, screening of titles and abstracts was performed by one reviewer (BB) against the eligibility criteria. A second reviewer (JML) corroborated the outcome of the searches. The outcome of the included studies was confirmed by two reviewers (OT and JML).

2.5. Data collection process and data items

The data was extracted from each article by a reviewer (BB) into a Microsoft Excel spreadsheet and confirmed by a second reviewer (JML). The data extraction form included: authors, year of publication, country, study design, setting, participants, exercise intervention and outcome measures.

2.6. Study risk of bias assessment

Quality assessment of the included studies was performed by two reviewers (BB, OT) using the Critical Appraisal Skills Program (CASP) checklists for single cohort studies [24], whereby a maximal score of 12 is available; and randomised controlled studies (RCT) [25], whereby a maximal score of 11 is available. A third reviewer (JML) confirmed the results and led the discussion towards consensus of the included studies. The CASP checklist items were marked “Y” (Yes) if well described, “N” (No) if inadequate, and unclear items with a “U” (Unclear). The use of CASP as a scoring framework was chosen as this can create a score across differing designs (i.e. cohort, RCT).

2.7. Effect measures

Only ppFEV1 and CFQ-R data was selected from the studies, as these are the most common variables obtained clinically and recommended by clinical guidelines [10]. All included studies reported ppFEV1 and/or CFQ-R respiratory and physical domain outcome measures. Measures of FEV1 are obtained using a spirometer and then normalised to a percentage of their predicted value. Quality of life is assessed using the CFQ-R for the respiratory and physical domains; whereby a value of 100 represented an optimal score.

2.8. Synthesis methods

The data of the included studies were transformed into a spreadsheet with study characteristics to provide an overview of the study methods, results and outcomes. The results of the included studies were synthesised based on the reported interventions and outcomes. Meta-analysis was not performed due to the different interventions within the included studies and no standardisation in measuring the outcomes. Therefore, the results are only synthesised based on the key findings of the outcome measures reported in the eight included studies.

3. Results

3.1. Study selection

Electronic and hand searches identified 392 studies, after removing duplicates, 346 citations were suitable for inclusion screening. Following screening of titles and abstracts, 43 full-text articles were retrieved. After assessing the articles against the inclusion criteria, eight studies were included in the review (Fig 1). Two of the included studies were identified through manual searching.

Fig 1. PRISMA Flow Chart.

Fig 1

3.2. Study characteristics

Eight studies with a total of 180 pwCF were included. A summary of the included study characteristics is presented in Table 2.

Table 2. Study characteristics.

Authors and Study Design Participant Demographics Intervention Comparison Outcomes and follow up
Carr et al., (2018) [32]
Randomised controlled pilot study
n = 40
Age: 6.1–51.5 years
Gender = 13M, 27F
CF diagnosed
Tai Chi lessons via Skype. Eight sets of Tai Chi-Qigong delivered 12w Tai Chi lessons face-to-face; 5–10 min, max. x5 p/w. Sample analysed: I: (n = 18); C: (n = 22) ppFEV1; CFQ-R Respiratory and Physical
Follow up: No follow up period
Drop-outs: n = 2: intervention
Chen et al., (2018) [26]
Single cohort intervention study
n = 10
Age: 8–20 years
Gender = not specified
CF diagnosed
Aerobic, resistance, and flexibility exercises via VSee telemedicine platform. 30-min sessions, 3x p/w, 6w No comparators Sample analysed: n = 10 Outcome: FEV1 in litres(L)
Follow up: No follow up period
Drop-outs: None reported
Cox et al., (2015) [29]
Single cohort intervention study
n = 10
Age: No age data available—adults
Gender = 4M, 6F
CF diagnosed
Internet-based physical activity via customised programme (ActivOnline).
8w total, fortnightly telephone consultation
No comparators. Sample analysed: n = 10 Outcome: CFQ-R Respiratory and Physical
Follow up: 8 weeks
Drop-outs: n = 0
Hommerding et al., (2015) [27]
Randomised controlled trial
n = 34
Age: 7–20 years
Gender = 20M,14F
CF diagnosed
Aerobic physical exercise programme with telephone calls every 2 weeks for 12w Control: Instructed on first day only, no follow-up.
Sample analysed: n = 34
Outcome: ppFEV1
Follow up: 12 weeks
Drop-outs: None reported
Rovedder et al., (2014) [30]
Randomised controlled trial
n = 41
Age:(mean; SD): 24.73; 7.57 years
Gender = 14M, 27F
CF diagnosed
Supervised home-exercise programme via telephone for 12w Control: Normal activities.
Sample analysed: n = 41
Outcome: ppFEV1
Follow up: 12 weeks–unclear?
Drop-outs: None reported
Schmidt et al., (2011) [28]
Single cohort intervention study
n = 24
Age: 14–40 years
Gender = 15M, 9F
CF diagnosed
Individualised exercise programme with weekly phone call. +30min, x3 p/w, 12w. Control.
Sample analysed: I: (n = 14); C: (n = 10) control (dropouts)
Outcome: ppFEV1
Follow up: No follow up period.
Drop-outs: n = 10.
Swisher et al., (2010) [31]
Single cohort intervention study
n = 12
Age: 7–17 years
Gender = 5M, 7F
CF diagnosed
Activity-based intervention with weekly follow-up phone calls for 12w. 10,000 step/day target No comparators.
Sample analysed: n = 12
Outcome: CFQ-R Respiratory and Physical
Follow up: No follow up period
Drop-outs: n = 2
Tomlinson et al., (2020) [33]
Single cohort intervention study
n = 9
Age: 15.5–42.1 years
Gender = 6M, 3F
CF diagnosed
Individualised exercise intervention conducted via Skype for 8w, supervised by an exercise therapist. No comparators.
Sample analysed: n = 7
Outcome: ppFEV1, CFQ-R Respiratory and Physical
Follow up: 4 weeks
Drop-outs: n = 2

I = intervention; C = control; M = male; F = female; w = week; p/w = per week. CFQ-R = Cystic Fibrosis Questionnaire–Revised; ppFEV1 = Forced Expiratory Volume in 1 second.

3.3. Risk of bias in studies

The overall CASP quality of reporting score for the included single cohort studies ranged from 2 to 7, with a mean score of 4.6 (out of a maximum possible score of 12). The CASP scores for the RCTs ranged from 6 to 7, with a mean score of 6.5 (out of a maximum possible of 11), as shown in Tables 3 and 4. The most common reasons for a low CASP score in the cohort studies were inaccurate measure of exposure and outcome to minimise bias, poor identification of confounding factors and inadequate follow up. Whereas, within the RCTs low scores were found due to inadequate blinding of participants, and poor reporting of the use of confidence intervals. The majority of studies included all post intervention outcome measures, however, one study did not report individual patient data for the assessed outcomes due to the risk of participant identification [26]. Full outcome datasets were not reported in three of the eight studies [2628].

Table 3. CASP Scores for Single Cohort Studies.

Study Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Item 7 Item 8 Item 9 Item 10 Item 11 Item 12 Total
Chen et al., 2018 [26] Y U U N N N N N Y Y Y U 4
Cox et al., 2015 [29] Y Y U N N N N N Y Y Y U 5
Schmidt et al., 2011 [28] Y U N N N N N N U U Y U 2
Swisher et al., 2010 [31] Y Y N N N N N N Y Y Y U 5
Tomlinson et al., 2020 [33] Y Y N N N Y N N Y Y Y Y 7

CASP: Critical Appraisal Skills Program. Y: Yes; N: No; U: Unclear.

Table 4. CASP Scores for Randomised Control Trials.

Study Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Item 7 Item 8 Item 9 Item 10 Item 11 Total
Carr et al., 2018 [32] Y Y Y N Y Y N N U Y Y 7
Hommerding et al., 2015 [27] Y Y Y N Y Y N N U Y Y 7
Rovedder et al., 2014 [30] Y Y Y N Y Y N N U Y N 6

CASP: Critical Appraisal Skills Program. Y: Yes; N: No; U: Unclear.

3.4. Synthesis of result

3.4.1. Study characteristics

The eight included studies consisted of 180 pwCF in total, of which 77 participants were male, however, one study had no gender ratio data available [26]. Two studies recruited adults only [29,30], three studies aimed to recruit children and adolescents [26,27,31] and two studies included participants from 6.1–51.5 years [28,32]. Sample sizes ranged from 9 to 41. Study designs included five single cohort intervention studies [26,28,29,31,33], two RCTs [27,30] and one feasibility trial [32]. Five studies did not have a control group [26,28,29,32,33].

3.4.2. Intervention characteristics

The method of telemedicine delivery was variable across studies (Table 2) with three online video-calling [26,32,33] and five telephone-based trials [2731]. Intervention duration ranged from 6–12 weeks, with many of the included studies lasting 12 weeks [27,28,30,31,33]. Exercise programmes were supervised in real-time for 3/8 studies [26,32,33], and unsupervised with telephone follow ups in 5/8 studies [2731].

The frequency of exercise varied from once a week to daily. Intensity of exercise was only stated in three studies [26,28,33]. Exercise session duration and intensity did not meet physical activity guidelines for 4/8 of the included studies [26,29,32,33] and was not reported in 3/8 studies [27,30,31]. The type of exercise differed within the included studies; seven studies used a combination of aerobic exercises, rather than focussing on one method [2631,33] (Table 2). Follow-up was often not performed [26,2831], participant withdrawals (n = 2–10) occurred in four studies [32,28,31,33] and two studies did not report withdrawals [26,27].

3.4.3. Outcomes

The main findings of the outcome measures are presented in Table 5. All included studies which measured ppFEV1 found no significant difference [2628,30,32,33]. However, the majority revealed a slight reduction in ppFEV1 [2628,30,33]. The validated CFQ-R was reported in five studies to provide an insight into patients perceived health [2831,33]. Five studies found improvements in the CFQ-R respiratory domain. For the CFQ-R physical domain, two studies found an improvement [29,30], and three studies showed reduced scores [28,31,33].

Table 5. Key findings of the outcome measures in the eight included studies.
Authors Control ppFEV1 CFQ-R Physical domain CFQ-R Respiratory domain
Carr et al., (2018) [32] Standard care control group Increased 1.47% predicted No significant differences reported No significant differences reported
Chen et al., (2018) [26] No comparators I:pre 85L vs I:post 81.5L*** Not reported Not reported
Cox et al., (2015) [29] No comparators Not reported I:pre 36 (32–67) vs I:post 63 (29–79) (p = 0.2) I:pre 33 (27–70)
vs I:post 44 (33–71) (p = 0.2)
Hommerding et al., (2015) [27] Standard care control group I:pre (95.5+/-17.9) vs I:post (93.7+/-8.6)
C:pre (100.1+/-21.2) vs C:post (99.1+/-14.2) (p = 0.5)
Not reported Not reported
Rovedder et al., (2014) [30] Standard care control group I:pre (58.3+/-27.6) vs C:pre (57.6+/-22.7) (p = 0.709)
I:post (52.3 +/-16.1) vs C:post (55.6+/-7.3) (p = 0.306)
I:pre 58 (*45/87) vs C:pre 64 (*44/81) (p = 1.000)
I:post (64.1+/-17.50) vs C:post 2.4+/-17.50 (*-10/13) (p = 0.742)
I:pre 55 (*50/72) vs
C:pre 55 (*38/61)
(p = 0.311)
I:post **3.8+/-10.60 (*0/11)
vs C:post **-4.7+/-13.40 (*-1/7)
(p = 0.925)
Schmidt et al., (2011) [28] No comparators I:pre 87.6 (74.8;105.8)
I:post 85.0 (76.5;99.0)
(p = 0.377)
I:pre (90.8+/-14.5) vs I:post
(93.8+/-8.1)
(p = 0.346)
I:pre (77.8+/-12.7) vs I:post (76.2+/-13.5)
(p = 0.371)
Swisher et al., (2010) [31] No comparators Not reported I:pre (86.1+/-10.4) vs I:post (81.8+/-15.0) I:pre (77.5+/-10.2) vs I:post (84.7+/-10.1)
Tomlinson et al., (2020)[33] No comparators I:pre (74+/-31) vs I:post (73+/-34) I:pre 72 (34) vs I:post 58 (37). I:pre 52 (33) vs I:post 56 (23)

I = intervention; C = control; pre = pre-intervention; post = post-intervention; *Author did not report full outcome dataset PRE vs POST; +/- = standard deviation; * = Median 25/75%; ** = difference;***ppFEV1 not reported–we query this value as Litres.

4. Discussion

The aim of this review was to investigate the effectiveness of telemedicine exercise interventions on ppFEV1 and QoL in pwCF. The eight included studies demonstrated that a variety of telemedicine-based exercises might have some benefit for pwCF. Improvements were found in the CFQ-R respiratory domain in five studies indicating a beneficial impact on perceived QoL [2831,33]. However, no significant benefits were reported on ppFEV1 which is a gold standard measure of respiratory system performance.

4.1. Interventions

There was substantial heterogeneity in the design of studies, and how these have each implemented interventions. For example, all studies using video-calling were published more recently from 2018–2020 [26,32,33], whereas studies testing telephone interventions were completed many years prior. This clearly shows the evolution towards online-based interventions within CF healthcare and a shift away from traditional methods. The COVID-19 pandemic has further accelerated the acceptance and use of telemedicine in pwCF and their clinical teams [34], as well as the general population. This aligns with the long term plans of the UK National Health Service, whereby the role of technology and telehealth is anticipated to substantially grow in the coming years [35,36].

The frequency of telemedicine guided exercises varied from once a week to daily and the intensity of exercise was only stated in three studies [26,28,33]. The majority of the studies utilised a combination of aerobic exercises, rather than focussing on one method [2631,33], and this heterogeneity in programmes may be due to the unique characteristics of pwCF, consolidating how they may require more specific individualised exercise programmes; whereby individualisation of programmes has been recently advocated for by international experts in exercise management of CF [37].

Within this review, the shorter interventions (6–8 weeks) were online-based [26,29,33], and thus within these studies, decreased ppFEV1 outcomes were reported, a finding corroborated by Radtke et al [38], who indicated that short-term conventional exercise interventions for pwCF did not show differences in outcomes. Moreover, only one study in our review met the WHO physical activity recommendations with over 75 minutes of vigorous intensity physical activity performed weekly. This suggests that the majority of interventions may not have been adequate to promote pulmonary function, and therefore, this intensity (or lack thereof), alongside the impact of intervention length, and the aforementioned variation in study design, means we cannot determine the efficacy of specific exercises at present. Therefore, longer study durations with rigorous follow-up may be required for telemedicine-based exercise interventions with people with CF.

4.2. Changes in function

The ppFEV1 findings within this review do not align with prior research in pwCF, which highlights ppFEV1 improvements following conventional exercise interventions [15]. On the other hand, a ppFEV1 decline of approximately -1.52% per year (95% CI: -1.66 to -1.38%) has been highlighted within the UK CF registry [39]. The minimal decline found within this review aligns with anticipated CF disease progression, therefore a focus on maintaining ppFEV1 may be more appropriate. The observed decreased of ppFEV1 results in our review may also be because the tested interventions might not meet the physiological requirements for pwCF specifically.

The CFQ-R respiratory domain outcomes in our review highlights that pwCF may perceive exercise as beneficial for their respiratory system function, despite the lack of improvement in objective ppFEV1 performance; thus highlighting the importance of including both objective, physical function, and subjective, psychological function, when evaluating interventions in disease groups. Interestingly, for the CFQ-R respiratory domain, reduced adherence was reported in both of the included studies that showed reduced scores [31,33], and within the wider CF population, it has been reported that adherence to conventional exercise programmes has been suboptimal [9,40,41]. For example, Rovedder et al [30] indicated that higher QoL scores were related to participants who performed more frequent telemedicine-based exercise, and highlighted the importance of adherence to tailored long-term programmes that meets the specific needs and preferences of pwCF.

The CFQ-R results of the included studies in our review testing telemedicine-based exercise are not consistent with conventional face-to-face exercises as reported by Hebestreit et al [15] who showed no change in the CFQ-R physical and respiratory domains among pwCF. Statistical significance was observed in our review and also not in the study of Hebestreit et al [15] This may be due to small sample sizes, different study aims and insufficient statistical power which limits the analysis of data to descriptive means.

4.3. Strengths & limitations

Whilst many strengths exist, notably this being the first study to systematically pool data on exercise-based telehealth interventions in this unique population, limitations of this review must be acknowledged. In the design of this review, grey literature was not assessed, non-English language articles were not included, and not all available databases were comprehensively searched, with only EBSCOhost used. Moreover, only a single-screener was used to filter results, which may introduce bias, although proportion of ‘missed’ studies in single-screened reviews is low (median of 5%) [42]. Another limitation of this review is the small sample sizes and heterogeneity in study designs and outcomes, thus precluding meta analyses and therefore limiting the strength of the conclusion and recommendations. Only eight studies were included within the review, despite a comprehensive search strategy, this highlights that there is currently limited evidence available. Generalisability and transferability of the results to clinical practice is limited due to methodological differences and variation in the study population and interventions.

5. Conclusion

The current review highlighted promising CFQ-R improvements within the respiratory and physical domains following 6–12 weeks of telemedicine-based exercise. However, no significant changes were found in ppFEV1 outcomes. This suggests that pwCF may find telemedicine-based exercise beneficial for enhancing their QoL, despite having no clear pulmonary function improvements.

The implication of this review on clinical practice and research is that caution should be applied when evaluating the evidence within the emerging field of telemedicine-based exercise for pwCF due to the methodological shortcomings and poor data quality within the included studies. Further large scale, high-quality RCTs with longer follow-up periods and standardised interventions would elucidate the impact of telemedicine-based exercise on ppFEV1 and QoL outcomes for pwCF further. The challenges will be recruitment to increase sample sizes, and provide robust statistical evidence that informs evidence-based guidelines and clinical practice. However, as this modality of intervention delivery is likely now a permanent fixture for CF in a post-pandemic landscape [34], it is likely that higher quality interventions will be developed and implemented in years to come.

Supporting information

S1 PRISMA Checklist. PRISMA Checklist.

(PDF)

Acknowledgments

The authors thank Andrew Sawyer, Research Advisor at Birmingham City University in Birmingham, UK, for his contribution to the search strategy development.

Data Availability

All available data are presented in the manuscript and associated files.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Kelly J. Environmental scan of cystic fibrosis research worldwide. J Cyst Fibros. 2017;16: 367–370. doi: 10.1016/j.jcf.2016.11.002 [DOI] [PubMed] [Google Scholar]
  • 2.Cystic Fibrosis Trust. UK Cystic Fibrosis Registry 2020 Annual Data Report. London, UK; 2021.
  • 3.Cystic Fibrosis Trust. Standards for the Clinical Care of Children and Adults with cystic fibrosis in the UK. London, UK; 2011.
  • 4.Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros. 2014;13 Suppl 1: S23–42. doi: 10.1016/j.jcf.2014.03.010 [DOI] [PubMed] [Google Scholar]
  • 5.Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2018. Bethesda MD, USA; 2019.
  • 6.Habib A-RR, Manji J, Wilcox PG, Javer AR, Buxton JA, Quon BS. A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis. Ann Am Thorac Soc. 2015;12: 420–428. doi: 10.1513/AnnalsATS.201408-393OC [DOI] [PubMed] [Google Scholar]
  • 7.Cystic Fibrosis Trust. Standards of Care and Good Clinical Practice for the Physiotherapy Management of Cystic Fibrosis. 4th Edn. London, UK; 2020.
  • 8.Konig P, Ner Z, Acton JD, Ge B, Hewett J. Is an FEV1 of 80% predicted a normal spirometry in cystic fibrosis children and adults? Clin Respir J. 2018;12: 2397–2403. doi: 10.1111/crj.12920 [DOI] [PubMed] [Google Scholar]
  • 9.Hurley N, Moyna NM, Kehoe B, McCaffrey N, Redmond K, Hardcastle SJ. Factors influencing physical activity in adults with cystic fibrosis. BMC Pulm Med. 2021;21: 113. doi: 10.1186/s12890-021-01482-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.National Institute for Health and Care Excellence (NICE). Cystic fibrosis: diagnosis and management. London, UK; 2017. Available: https://www.nice.org.uk/guidance/ng78 [PubMed]
  • 11.Shei R-J, Mackintosh KA, Peabody Lever JE, McNarry MA, Krick S. Exercise Physiology Across the Lifespan in Cystic Fibrosis. Front Physiol. 2019;10. doi: 10.3389/fphys.2019.01382 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gruet M, Saynor ZL, Urquhart DS, Radtke T. Rethinking physical exercise training in the modern era of cystic fibrosis: A step towards optimising short-term efficacy and long-term engagement. J Cyst Fibros. 2022;21: e83–e98. doi: 10.1016/j.jcf.2021.08.004 [DOI] [PubMed] [Google Scholar]
  • 13.Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020;54: 1451–1462. doi: 10.1136/bjsports-2020-102955 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.McLeod C, Wood J, Tong A, Schultz A, Norman R, Smith S, et al. The measurement properties of tests and tools used in cystic fibrosis studies: a systematic review. Eur Respir Rev. 2021;30. doi: 10.1183/16000617.0354-2020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hebestreit H, Schmid K, Kieser S, Junge S, Ballmann M, Roth K, et al. Quality of life is associated with physical activity and fitness in cystic fibrosis. BMC Pulm Med. 2014;14: 26. doi: 10.1186/1471-2466-14-26 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Shelley J, Boddy LM, Knowles ZR, Stewart CE, Dawson EA. Physical activity and associations with clinical outcome measures in adults with cystic fibrosis; a systematic review. J Cyst Fibros. 2019;18: 590–601. doi: 10.1016/j.jcf.2019.03.003 [DOI] [PubMed] [Google Scholar]
  • 17.Cox NS, Alison JA, Button BM, Wilson JW, Morton JM, Holland AE. Physical activity participation by adults with cystic fibrosis: An observational study. Respirology. 2016;21: 511–518. doi: 10.1111/resp.12719 [DOI] [PubMed] [Google Scholar]
  • 18.World Health Organization. From innovation to implementation: eHealth in the WHO European Region. Copenhagen, Denmark; 2016.
  • 19.Blandford A, Wesson J, Amalberti R, AlHazme R, Allwihan R. Opportunities and challenges for telehealth within, and beyond, a pandemic. Lancet Glob Health. 2020;8: e1364–e1365. doi: 10.1016/S2214-109X(20)30362-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.World Health Organization. Global strategy on digital health 2020–2025. Geneva, Switzerland; 2021.
  • 21.Cox NS, Alison JA, Button BM, Wilson JW, Holland AE. Assessing exercise capacity using telehealth: a feasibility study in adults with cystic fibrosis. Respir Care. 2013;58: 286–90. doi: 10.4187/respcare.01922 [DOI] [PubMed] [Google Scholar]
  • 22.Selzler A-M, Wald J, Sedeno M, Jourdain T, Janaudis-Ferreira T, Goldstein R, et al. Telehealth pulmonary rehabilitation: A review of the literature and an example of a nationwide initiative to improve the accessibility of pulmonary rehabilitation. Chron Respir Dis. 2018;15: 41–47. doi: 10.1177/1479972317724570 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. doi: 10.1136/bmj.n71 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Critical Appraisal Skills Program. CASP Cohort Study Checklist. 2018. Available: https://casp-uk.net/casp-tools-checklists/ [Google Scholar]
  • 25.Critical Appraisal Skills Program. CASP Randomised Controlled Trial Standard Checklist. 2020. Available: https://casp-uk.net/casp-tools-checklists/ [Google Scholar]
  • 26.Chen JJ, Cooper DM, Haddad F, Sladkey A, Nussbaum E, Radom-Aizik S. Tele-Exercise as a Promising Tool to Promote Exercise in Children With Cystic Fibrosis. Front Public Health. 2018;6. doi: 10.3389/fpubh.2018.00269 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Hommerding PX, Baptista RR, Makarewicz GT, Schindel CS, Donadio MV, Pinto LA, et al. Effects of an educational intervention of physical activity for children and adolescents with cystic fibrosis: a randomized controlled trial. Respir Care. 2015;60: 81–87. doi: 10.4187/respcare.02578 [DOI] [PubMed] [Google Scholar]
  • 28.Schmidt AM, Jacobsen U, Bregnballe V, Olesen HV, Ingemann-Hansen T, Thastum M, et al. Exercise and quality of life in patients with cystic fibrosis: A 12-week intervention study. Physiother Theory Pract. 2011;27: 548–556. doi: 10.3109/09593985.2010.545102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Cox NS, Alison JA, Button BM, Wilson JW, Holland AE. Feasibility and acceptability of an internet-based program to promote physical activity in adults with cystic fibrosis. Respir Care. 2015;60: 422–9. doi: 10.4187/respcare.03165 [DOI] [PubMed] [Google Scholar]
  • 30.Rovedder PME, Flores J, Ziegler B, Casarotto F, Jaques P, Barreto SSM, et al. Exercise programme in patients with cystic fibrosis: A randomized controlled trial. Respir Med. 2014;108: 1134–1140. doi: 10.1016/j.rmed.2014.04.022 [DOI] [PubMed] [Google Scholar]
  • 31.Swisher A, Moffett K. The Effect of Coaching on Physical Activity and Quality of Life in Children and Adolescents with Cystic Fibrosis: A Quality Improvement Pilot Study. Internet J Allied Health Sci Pract. 2010;8. doi: 10.46743/1540-580X/2010.1292 [DOI] [Google Scholar]
  • 32.Carr SB, Ronan P, Lorenc A, Mian A, Madge SL, Robinson N. Children and Adults Tai Chi Study (CF-CATS2): a randomised controlled feasibility study comparing internet-delivered with face-to-face Tai Chi lessons in cystic fibrosis. ERJ Open Res. 2018;4: 00042–02018. doi: 10.1183/23120541.00042-2018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Tomlinson OW, Shelley J, Trott J, Bowhay B, Chauhan R, Sheldon CD. The feasibility of online video calling to engage patients with cystic fibrosis in exercise training. J Telemed Telecare. 2020;26: 356–364. doi: 10.1177/1357633X19828630 [DOI] [PubMed] [Google Scholar]
  • 34.Tomlinson OW, Saynor ZL, Stevens D, Urquhart DS, Williams CA. The impact of COVID-19 upon the delivery of exercise services within cystic fibrosis clinics in the United Kingdom. Clin Respir J. 2022;16: 335–340. doi: 10.1111/crj.13484 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Carter C. Operational Productivity and Performance in English NHS Acute Hospitals: Unwarranted Variations—An Independent Report for the Department of Health. Department of Health and Social Care; 2016. [Google Scholar]
  • 36.Maruthappu M, Sood HS, Keogh B. The NHS Five Year Forward View: transforming care. Br J Gen Pract. 2014;64: 635. doi: 10.3399/bjgp14X682897 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Williams CA, Barker AR, Denford S, van Beurden SB, Bianchim MS, Caterini JE, et al. The Exeter Activity Unlimited statement on physical activity and exercise for cystic fibrosis: methodology and results of an international, multidisciplinary, evidence-driven expert consensus. Chron Respir Dis. 2022;19: 147997312211216. doi: 10.1177/14799731221121670 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Radtke T, Nevitt SJ, Hebestreit H, Kriemler S. Physical exercise training for cystic fibrosis. Cochrane Database Syst Rev. 2017;11: CD002768. doi: 10.1002/14651858.CD002768.pub4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Caley L, Smith L, White H, Peckham DG. Average rate of lung function decline in adults with cystic fibrosis in the United Kingdom: Data from the UK CF registry. J Cyst Fibros. 2021;20: 86–90. doi: 10.1016/j.jcf.2020.04.008 [DOI] [PubMed] [Google Scholar]
  • 40.Cox NS, Alison JA, Button BM, Wilson JW, Morton JM, Holland AE. Accumulating physical activity in at least 10-minute bouts predicts better lung function after 3-years in adults with cystic fibrosis. ERJ Open Res. 2018;4. doi: 10.1183/23120541.00095-2017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Santuzzi CH, Liberato FMG, Morau SAC, de Oliveira NFF, Nascimento LR. Adherence and barriers to general and respiratory exercises in cystic fibrosis. Pediatr Pulmonol. 2020;55: 2646–2652. doi: 10.1002/ppul.24912 [DOI] [PubMed] [Google Scholar]
  • 42.Waffenschmidt S, Knelangen M, Sieben W, Bühn S, Pieper D. Single screening versus conventional double screening for study selection in systematic reviews: a methodological systematic review. BMC Med Res Methodol. 2019;19: 132. doi: 10.1186/s12874-019-0782-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLOS Digit Health. doi: 10.1371/journal.pdig.0000201.r001

Decision Letter 0

Padmanesan Narasimhan, Yuan Lai

8 Nov 2022

PDIG-D-22-00220

A systematic review to explore how exercise-based physiotherapy via telemedicine can promote health related benefits for people with cystic fibrosis

PLOS Digital Health

Dear Dr. Tomlinson,

Thank you for submitting your manuscript to PLOS Digital Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Digital Health's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript within 30 days Dec 08 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at digitalhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pdig/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

* A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Yuan Lai, Ph.D.

Academic Editor

PLOS Digital Health

Journal Requirements:

1. We have amended your Competing Interest statement to comply with journal style. We kindly ask that you double check the statement and let us know if anything is incorrect.

2. Please send a completed 'Competing Interests' statement, including any COIs declared by your co-authors. If you have no competing interests to declare, please state "The authors have declared that no competing interests exist". Otherwise please declare all competing interests beginning with the statement "I have read the journal's policy and the authors of this manuscript have the following competing interests:"

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article's retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does this manuscript meet PLOS Digital Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

Reviewer #3: Yes

--------------------

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

Reviewer #3: Yes

--------------------

3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

--------------------

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Digital Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

--------------------

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Below I provide section by section, critique of the shortcomings of the manuscript:

Eligibility Criteria: Some justification is needed for how and why the eligibility criteria was designed to be how it is.

Justification is needed for why only three databases searched and why were these three databases selected. specifically, PUBMED seems to be concerningly absent from the list of databases

Selection Process: "A second reviewer (JML) performed the outcome of the searches" -- meaning of this sentence is unclear.

Selection Process: Authors need to address the fact that the initial search and screening was only conducted by one person -- this is highly unusual for systematic reviews. this needs to be addressed as a limitation of this study as this is major source of bias in this review.

Study Risk of Bias Assessment: A risk bias assessment of the review itself needs to be conducted and reported. Consider ROBIS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687950/

Effect Measures: Why were only ppFEV and CFQ-R data selected from the study? Simply the fact that all studies reported these is a shallow justification and does not give the reader a robust understanding of this decision.

3.3. Risk of Bias in Studies: The authors should provide more context for what the CASP score means; a mean score of 4.6 for single cohort studies does not mean much to a reader not familiar with CASP.

3.4. Synthesis of Results: Authors should consider using sub-sections to structure their results synthesis section and thus adding more hierarchy to their reported results and framing the findings of the review more clearly.

Authors should recognize that results of a review are not simply the outcomes of the reviewed studies but also their intervention and experimental designs. For example, In the results section, the authors should also report on how user adherence to telemedicine programs were measured and how this impacted the outcomes of the reviewed studies.

4. Discussion: The authors should use sections to structure their discussion and frame their argument.

The discussion sections requires significant work to be publishable. Authors need to clearly report on the state of this topic, address specific shortcomings, comment on the impact of the shortcomings on the lackluster results of the reviewed studies and suggest robust guidelines for future work in this area. Currently, the discussion sections reads more like a results sections, than their current results section. For instance, there needs to be discussion on the contents of the various Tables provided in this section in context of their impact on the reviewed studies and how they can be used to inform improved future studies.

Reviewer #2: Thank you for this interesting and important topic, your manuscript is organized and written very well, and the discussion is strong. The only concern is that your manuscript sounds like a literature review of 8 articles but as you mentioned that it was because of a lack of enough studies in the literature.

Reviewer #3: The health-related benefits of exercise-based physiotherapy via telemedicine is an important question to the CF community at this time. Post-pandemic, in CF centres across the UK physiotherapists continue to spend time developing and carrying out online-exercise programmes for people with CF in order to meet the changing needs of the CF population. It is so important that we begin to discuss and assess the value of these programmes so that we can begin to define what a quality CF physiotherapy telemedicine exercise programme looks like to inform our future strategy. This paper will therefore have broad interest within the CF community.

The report shows excellent methodological design which is described in enough detail to be reproduced in future reviews.

The conclusions are appropriate for the report's findings.

The report is well organised, easy to read and understand.

--------------------

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Nisreen Al Jallad

Reviewer #3: Yes: Catherine Brown

--------------------

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Digit Health. doi: 10.1371/journal.pdig.0000201.r003

Decision Letter 1

Padmanesan Narasimhan, Yuan Lai

24 Jan 2023

A systematic review to explore how exercise-based physiotherapy via telemedicine can promote health related benefits for people with cystic fibrosis

PDIG-D-22-00220R1

Dear Mr Tomlinson,

We are pleased to inform you that your manuscript 'A systematic review to explore how exercise-based physiotherapy via telemedicine can promote health related benefits for people with cystic fibrosis' has been provisionally accepted for publication in PLOS Digital Health.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow-up email from a member of our team. 

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact digitalhealth@plos.org.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Digital Health.

Best regards,

Yuan Lai, Ph.D.

Academic Editor

PLOS Digital Health

***********************************************************

Reviewer Comments (if any, and for reference):

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Does this manuscript meet PLOS Digital Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Digital Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for addressing my previous comments. I believe the current versions of the manuscript represents a significant improvement over the previous version. Thank you for all your hardwork in making these improvement; It will be a great resource for furthering future research in this domain.

Reviewer #2: Well done

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Nisreen Al Jallad

**********

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 PRISMA Checklist. PRISMA Checklist.

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All available data are presented in the manuscript and associated files.


    Articles from PLOS Digital Health are provided here courtesy of PLOS

    RESOURCES